Halozyme Reports Fourth Quarter and Full Year 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Halozyme Therapeutics (HALO) Misses Q4 EPS by 9c, Offers Guidance
February 24, 2020 4:24 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.24), $0.09 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $53.7 million versus the consensus estimate of $56.93 million.
GUIDANCE:
Halozyme Therapeutics sees FY2020 EPS of $0.60-$0.75, versus the consensus of $0.58.... More
